RSV

FDA Grants Approval to Pfizer’s Innovative RSV Vaccine for Infants

by

Pfizer’s groundbreaking RSV vaccine tailored for infants, known as Abrysvo, has successfully secured approval from the Food and Drug Administration (FDA).

Responsible for triggering up to 80,000 pediatric hospitalizations and 300 pediatric fatalities annually in the United States, the respiratory syncytial virus (RSV) is a significant health concern. While most infants who contract RSV experience mild respiratory symptoms such as congestion, cough, and fatigue, there’s a subset that encounters breathing difficulties and potential complications like pneumonia.

Vaccines Against Three Respiratory Viruses Offer Hope for Upcoming Season

by

As we approach the upcoming respiratory virus season, the memory of last year’s harsh ordeal remains fresh. After experiencing two remarkably light flu seasons due to pandemic precautions like social distancing and masking, the return of influenza was fierce, arriving early and causing a widespread impact.

In tandem, the respiratory syncytial virus (RSV), which had sporadically appeared throughout the year, surged during the winter months, resulting in one of the most severe RSV seasons in recent memory. To compound matters, COVID-19 cases showed a resurgence, a familiar situation after three years of successive waves.